

# Rapid Acting Insulin Market | Asia-Pacific region would exhibit the highest CAGR of 4.1% during 2020-2027.

*The rapid acting insulin market size and estimations are based on a comprehensive analysis of key developments in the industry.*

PORTLAND, OREGON, UNITED STATES, August 29, 2022 /EINPresswire.com/ -- Which insulin drugs are rapid acting?

Insulin aspart (Novorapid) – takes effect approximately 10-20 minutes after injection. Insulin aspart (Fiasp) – takes effect approximately 5 minutes after injection. Insulin lispro (Humalog) – takes effect approximately 15-30 minutes after injection.



The global [rapid acting insulin market](#) size was valued at \$7,100 million in 2019, and is projected to reach \$8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027.

The growth of the global rapid acting insulin market is driven by increase in prevalence of diabetes, surge in geriatric population who are susceptible to develop diabetes, and surge in adoption of sedentary lifestyle. These factors contribute to the growth of the industry during the forecast period.

Download Sample Report at: <https://www.alliedmarketresearch.com/request-sample/10964>

Rise in availability of continuous glucose monitoring, surge in investments in R&D for human recombinant insulin, and increase in government expenditure on healthcare drive the growth of the global rapid acting insulin market. However, adverse effects associated with use of rapid acting insulin hinder the market growth. On the contrary, undiagnosed population in developing region is estimated to open lucrative opportunities for market players in the future.

Covid-19 scenario:

The patients suffering from respiratory diseases and diabetes are at higher risk of getting infected by Covid-19 virus. Thus, the demand for rapid acting insulin has increased during the pandemic.

However, the prolonged lockdown across various countries have disrupted the supply chain and increased the prices of raw materials.

The pandemic and restriction on international trade has created challenges for manufacturing and distribution of rapid acting insulin.

Rapid acting insulin is one of the fastest acting insulin that starts working within 15 minutes of its introduction. Action of this insulin is supposed to last for 5 hours. These analogs are frequently chosen over regular insulin due to their faster response, which allows diabetes patients to take it intravenously before any meal. It is usually taken post meals as it functions like natural insulin by reducing the risk of low blood glucose. Some of the rapid acting insulin available in the market are Humalog, Fiasp, NovoRapid, Apidra and others. Rapid acting insulin is usually preferred in pumps that deliver small amounts of insulin into the body every few minutes.

The online providers segment to manifest the highest CAGR through 2027

By distribution channel, the online providers segment is projected to portray the highest CAGR of 6.9% from 2020 to 2027. However, the drug store & retail pharmacies segment held the largest share in 2019, contributing to nearly two-thirds of the global rapid acting insulin market, owing to availability of rapid acting insulin in drug store & retail pharmacy stores.

Enquiry for Short-term and Long-term Impacts of COVID-19 at:  
<https://www.alliedmarketresearch.com/purchase-enquiry/10964>

North America held the largest share

By region, the market across North America held the largest share in 2019, contributing to nearly half of the market, due to rise in incidences of diabetes, high number of geriatric population, and favorable government policies. However, the global rapid acting insulin market across Asia-Pacific is estimated to register the highest CAGR of 5.8% during the forecast period, owing to westernized lifestyle behaviors and the increased prevalence of obesity.

Major market players

Biocon Limited  
ADOCIA SAS  
Gan & Lee Pharmaceuticals  
Eli Lilly and Company

Mannkind Corporation  
Geropharm LLC  
Sanofi S.A.  
Novo Nordisk A/S  
Wockhadt Ltd.

We also Offers Regional and Country Reports-

Japan Rapid Acting Insulin Market  
South Korea Rapid Acting Insulin Market  
Singapore Rapid Acting Insulin Market  
China Rapid Acting Insulin Market  
Indonesia Rapid Acting Insulin Market  
Australia Rapid Acting Insulin Market  
Taiwan Rapid Acting Insulin Market

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

David Correa  
Allied Analytics LLP  
+1 800-792-5285  
[email us here](#)

Visit us on social media:

[Facebook](#)  
[Twitter](#)  
[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/588317275>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.